Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with decompensated HF. We prospectively enrolled patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Takahiro, Yasuda, Yoko, Okamoto, Hitomi, Saito, Yuji, Nakano, Yusuke, Matsuura, Katsuhiko, Oonishi, Masafumi, Amano, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134766/
https://www.ncbi.nlm.nih.gov/pubmed/37102627
http://dx.doi.org/10.1002/prp2.1088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134766/
https://www.ncbi.nlm.nih.gov/pubmed/37102627
http://dx.doi.org/10.1002/prp2.1088

Ejemplares similares